pharma · Breast Cancer · NSCLC, synchronous oligo-metastatic
Impact Therapeutics
Partner Therapeutics Limited
Partner Therapeutics is a pharma organization headquartered in GB. Primary therapeutic focus areas include Breast Cancer, NSCLC, synchronous oligo-metastatic, Solid Tumors, ER-positive/HER2-negative early breast cancer,
1004, 10th Floor, Lodha Supremus Saki Vihar Road, Powai, Mumbai-400072, Maharashtra 400072, IN, Lexington HQ
2010 Founded
8 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- 1004, 10th Floor, Lodha Supremus Saki Vihar Road, Powai, Mumbai-400072, Maharashtra 400072, IN, Lexington
- Founded
- 2010
- Employees
- 8
- Programs
- 12
- Drugs
- 26
- Patents
- 0
Tarlatamab, Tarlatamab
Phase 2 · small molecule · Patients with pretreated extensive-stage small cell lung cancer (ES-SCLC) and ECOG PS 2
Tarlatamab, Tarlatamab for Patients with pretreated extensive-stage small cell lung cancer (ES-SCLC) and ECOG PS 2 is a Phase 2 program (small_molecule) at Partner Therapeutics Limited with 1 ClinicalTrials.gov record(s).
Internal code ETOP29-25 START-lung
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Partner Therapeutics Limited
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Patients with pretreated extensive-stage small cell lung cancer (ES-SCLC) and ECOG PS 2
- Status
- active
- Trials
- 1